OakChart

Propanc Biopharma Inc

PPCBHealthcare·Biotechnology·Australia·Nano·NASD·Nov 11 • 11:37 AM ET

1.82+0.08 (4.70%)
2026-11-11 17:41 CET
Market cap
1.80 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-19.79 USD m
Free cash flow, TTM
-5.95 USD m
EPS diluted, TTM
-258.08
P/E
-
Compare

Price

PPCB against its 20, 50 and 200-day averages
2050200
0.00100.00200.00300.008.7M17.5MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PPCBclose 1.8220-day 2.3350-day 4.90200-day 20.561.8252w high

99.4% under the 52-week high of 315.00 on 1 Dec 2025. 52-week low 1.63 on 5 Nov 2026. Last 15 sessions, 84.8% high to low

Profile

PPCB
52-week range, 0% of the way up
1.63315

Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm focuses on the treatment of pancreatic, ovarian, and colorectal cancer. It offers its product pipeline, including PRP and POP1. The company was founded by James Nathanielsz and Julian Kenyon on October 15, 2007 and is headquartered in Camberwell, Australia.

Employees2
IPONov 12, 2012
Beta3.32
ATR, 14d0.40
Rel volume0.08
Inst own0.67%

Snapshot

6 groups

Valuation

Index-
Market Cap1.88M
Enterprise Value1.56M
Income-19.79M
Sales0.00M
Book/sh28.40
Cash/sh0.80
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees2
IPONov 12, 2012

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.06
P/C2.27
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio2.55
Current Ratio2.55
Debt/Eq0.05
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-258.08
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y98.13% 97.29%
Sales past 3/5Y- -
EPS Y/Y TTM98.74%
Sales Y/Y TTM-
EPS Q/Q84.24%
Sales Q/Q-
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own-
Insider Trans-
Inst Own0.67%
Inst Trans-
ROA-116.39%
ROE-161.86%
ROIC-200.12%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-21.88%
SMA50-62.83%
SMA200-91.14%
Trades-

Technical

Shs Outstand0.33M
Shs Float-
Short Float-
Short Ratio0.11
Short Interest0.02M
52W High315.00 -99.42%
52W Low1.63 11.77%
Volatility8.14% 12.48%
ATR (14)0.40
RSI (14)26.28
Beta3.32
Rel Volume0.08
Avg Volume184.88K
Volume5,635

Performance

Perf Week1.78%
Perf Month-55.84%
Perf Quarter-85.07%
Perf Half Y-92.16%
Perf YTD-98.64%
Perf Year-99.13%
Perf 3Y-100.00%
Perf 5Y-100.00%
Perf 10Y-100.00%
Recom-
Target Price380.00
Prev Close1.74
Price1.82
Change %4.70%

Peers

Mkt cap
TickerCompanyMkt cap
PMCBPharmaCyte Biotech Inc4.51M
SLXNSilexion Therapeutics Corp1.97M
NCNANuCana plc ADR3.97M
PCSAProcessa Pharmaceuticals Inc5.43M
RNXTRenovoRx Inc59.84M
ONCYOncolytics Biotech Inc50.24M
ELTXElicio Therapeutics Inc44.15M
IMMPImmutep Limited ADR26.24M
KZIAKazia Therapeutics Limited ADR86.98M
ATHEAlterity Therapeutics Ltd ADR43.45M

News

latest 14 of 118
  • Propanc Biopharma Reports Preclinical Data with PRP & PRP plus TGF-ß Inhibitor on TGF-ß Pathway in Pancreatic Cancer (GlobeNewswire) -6.52%
  • Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients (GlobeNewswire) -12.80%
  • Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients (GlobeNewswire) -13.17%
  • Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability (GlobeNewswire) -18.21%
  • CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans (GlobeNewswire) -13.13%
  • Loading…
  • Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans (GlobeNewswire)
  • Propanc Biopharma's Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells (GlobeNewswire)
  • Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer (GlobeNewswire) -11.35%
  • Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines' Daraxonrasib (GlobeNewswire)
  • Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results (GlobeNewswire)
  • Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015 (GlobeNewswire)
  • Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc. (GlobeNewswire) -22.56%
  • Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027 (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-2699460107973760-164511097780505-2886172765407.6-11956058788.207-738302339.454-26968656.269-355128.974-3712.24-176.157
Period201820192020202120222023202420252026
EPS, quarterly-11247.75-8998.2-8248.35-3124.563-87.658-98.078-75.29-70.9-13.813
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26
Sales, annual000000000
Period201820192020202120222023202420252026
Sales, quarterly000000000
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26
Shares, annual--000000.0460.331
Period201820192020202120222023202420252026
Shares, quarterly0000.0460.0460.0510.0540.0870.331
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26

Income statement, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.020.020.020.020.020.010.000.000.00
Gross Profit-0.02-0.02-0.02-0.02-0.02-0.01-0.00-0.00-0.00
Selling, General and Administrative Excl. Other18.1618.1657.261.511.751.991.813.492.61
Research and Development0.630.630.220.250.250.260.230.180.26
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-18.19-18.19-57.28-1.54-1.78-1.99-1.81-3.49-2.61
Interest Expense0.430.430.560.670.530.570.451.751.31
Unusual Expense0.270.270.66-0.370.490.12-0.09-0.451.25
Net Income Before Taxes-18.86-18.86-58.92-1.95-2.79-2.71-2.14-4.88-5.87
Income Taxes0.000.000.00-0.13-0.13-0.05-0.11-0.13-0.12
Consolidated Net Income-18.86-18.86-58.92-1.82-2.66-2.66-2.03-4.74-5.76
Net Income From Continuing Operations-18.86-18.86-58.92-1.82-2.66-2.66-2.03-4.74-5.76
Net Income-19.79-19.79-58.92-2.01-3.13-3.36-2.42-4.74-5.76
EPS (Recurring)-59.21-174.46-3,683.20-400,869.61-24,029,977.57-720,175,208.80-12,409,570,000.02--
EPS (Basic, Before Extraordinaries)-258.08-176.16-3,712.24-355,128.97-26,968,656.27-738,302,339.45-11,956,058,788.21-2,886,172,765,407.63-164511097780505
EPS (Diluted)-258.08-176.16-3,712.24-355,128.97-26,968,656.27-738,302,339.45-11,956,058,788.21-2,886,172,765,407.63-164511097780505
EBITDA-18.16-18.16-57.26-1.51-1.75-1.99-1.81-3.49-2.61
Non-Operating Income (Expense)0.030.03-0.42-0.120.01-0.040.03-0.09-0.69
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense14.6321.9951.330.000.000.050.080.30-
Shares Outstanding0.330.330.050.000.000.000.002E-11-
Market Capitalization1.801.8048.191.378.148.157.2710.070.00

Income statement, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q32025Q22025Q1
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.010.010.000.010.010.000.01
Gross Profit-0.01-0.01-0.01-0.00-0.01-0.01-0.00-0.01
Selling, General and Administrative Excl. Other3.456.393.654.673.6453.120.210.29
Research and Development0.380.170.020.060.050.050.050.06
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.46-6.40-3.65-4.67-3.65-53.13-0.21-0.29
Interest Expense0.030.040.060.310.250.100.120.09
Unusual Expense1.14-0.00-0.70-0.18-0.070.760.01-0.04
Net Income Before Taxes-4.57-6.36-3.09-4.84-4.07-54.07-0.43-0.35
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-4.57-6.36-3.09-4.84-4.07-54.07-0.43-0.35
Net Income From Continuing Operations-4.57-6.36-3.09-4.84-4.07-54.07-0.43-0.35
Net Income-4.57-6.36-4.02-4.84-4.07-54.07-0.43-0.35
EPS (Recurring)-11.39-70.90-84.40-100.58-88.68-3,093.70-8,147.95-9,728.46
EPS (Basic, Before Extraordinaries)-13.81-70.90-75.29-98.08-87.66-3,124.56-8,248.35-8,998.20
EPS (Diluted)-13.81-70.90-75.29-98.08-87.66-3,124.56-8,248.35-8,998.20
EBITDA-3.45-6.39-3.65-4.67-3.64-53.12-0.21-0.29
Non-Operating Income (Expense)0.060.08-0.07-0.03-0.24-0.07-0.09-0.02
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense10.411.751.790.68---0.01
Shares Outstanding0.330.090.050.050.050.050.000.00
Market Capitalization1.802.327.2221.7748.1963.860.170.21

Balance sheet, annual

Currency USD, millions
Metric2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments0.830.010.020.010.000.000.070.000.02
Short Term Receivables0.010.010.000.000.000.000.000.010.01
Inventories0.000.000.000.000.000.000.000.00-
Other Current Assets7.708.340.000.010.010.000.000.080.03
Total Current Assets8.548.350.030.020.020.010.070.090.06
Net Property, Plant & Equipment0.040.060.020.040.060.000.030.010.01
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Other Assets4.1911.220.030.000.000.000.000.000.00
Total Assets12.7819.630.070.060.080.010.100.100.07
Short Term Debt Incl. Current Port. of LT Debt0.491.580.890.460.950.591.501.564.55
Accounts Payable1.131.251.210.970.941.000.840.921.16
Other Current Liabilities1.742.751.691.731.171.491.401.931.12
Total Current Liabilities3.355.583.793.163.063.083.744.406.82
Long Term Debt0.020.150.060.020.040.000.000.00-
Provision for Risks Charges0.000.000.000.000.000.000.000.00-
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities3.385.733.853.183.113.083.744.406.82
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value2E-060.000.000.000.010.010.010.010.01
Common Equity9.4013.91-3.78-3.12-3.03-3.07-3.65-4.31-6.76
Total Shareholders Equity9.4013.91-3.78-3.12-3.02-3.07-3.64-4.30-6.75
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity9.4013.91-3.78-3.12-3.02-3.07-3.64-4.30-6.75
Total Liabilities & Stockholders Equity12.7819.630.070.060.080.010.100.100.07
Book Value Per Share28.40299.40-118,367.28-7,751,091.61-206,170,796.46-3,268,694,680.85-182,321,250,000.23--
Tangible Book Value Per Share28.40299.40-118,367.28-7,751,091.61-206,170,796.46-3,268,694,680.85-182,321,250,000.23--
Full-Time Employees222232332
Price to Book Ratio0.063.47-0.37-2.61-2.69-2.37-2.76-566,950,141,772.97-2292813073346560
Return on Assets-116.39-598.08-2,743.97-3,747.83-5,610.62-3,630.11-4,736.70-6,655.57-8,457.68
Return on Equity-161.86-1,163.67-------
Return on Invested Capital-200.12-419.28-------
Quick Ratio2.551.500.010.010.000.000.020.02-
Current Ratio2.551.500.010.010.000.000.020.020.01

Cash flow, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-19.75-18.86-58.92-1.82-2.66-2.66-2.03-4.74-5.76
Depreciation0.020.020.020.020.020.010.000.000.00
Other Funds (Non Cash)14.3913.7457.360.451.061.050.442.683.19
Funds from Operations-5.34-5.10-1.54-1.35-1.58-1.60-1.58-2.06-2.56
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.61-0.581.140.420.470.170.440.210.50
Cash from Operating Activities-5.95-5.68-0.41-0.94-1.11-1.44-1.15-1.85-2.06
Capital Expenditures-0.01-0.000.000.000.000.000.000.00-0.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.01-0.000.000.000.000.000.000.00-0.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock7.617.260.000.020.500.720.780.451.10
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock7.617.260.000.020.500.720.780.451.10
Proceedsfrom Stock Options4.464.260.000.020.020.100.000.451.10
Issuance or Reduction of Debt, Net-0.85-0.810.490.920.590.770.281.471.03
Change in Long Term Debt-0.11-0.110.080.300.000.000.000.000.00
Issuance of Long Term Debt0.080.080.080.300.000.000.000.000.00
Reduction of Long Term Debt-0.19-0.190.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.020.000.00-0.03-0.02
Other Financing Activities Uses-0.000.000.000.000.000.00-0.03-0.02
Cash from Financing Activities6.766.460.490.941.111.491.061.892.12
Exchange Rate Effect0.050.05-0.090.00-0.00-0.050.020.02-0.07
Net Change in Cash0.860.82-0.010.010.010.00-0.060.06-0.02
Free Cash Flow-5.95-5.69-0.41-0.94-1.11-1.44-1.15-1.85-2.06
Preferred Dividends (Cash Flow)--0.00------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q3
Cash & Short Term Investments0.830.440.560.600.010.05
Short Term Receivables0.010.010.020.010.010.00
Inventories0.000.000.000.000.000.00
Other Current Assets7.707.777.138.158.349.68
Total Current Assets8.548.227.718.768.359.74
Net Property, Plant & Equipment0.040.050.060.060.060.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets4.196.067.359.1511.2212.79
Total Assets12.7814.3315.1117.9819.6322.53
Short Term Debt Incl. Current Port. of LT Debt0.490.540.610.651.581.15
Accounts Payable1.130.970.961.071.251.12
Other Current Liabilities1.741.962.051.852.752.07
Total Current Liabilities3.353.483.623.575.584.34
Long Term Debt0.021.031.040.040.150.09
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities3.384.514.663.615.734.44
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value2E-060.000.000.000.000.00
Common Equity9.409.8310.4514.3613.9118.09
Total Shareholders Equity9.409.8310.4514.3613.9118.09
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity9.409.8310.4514.3613.9118.09
Total Liabilities & Stockholders Equity12.7814.3315.1117.9819.6322.53
Book Value Per Share28.40112.40194.28280.34299.40389.52
Tangible Book Value Per Share28.40112.40194.28280.34299.40389.52
Full-Time Employees2---2-
Price to Book Ratio0.060.240.691.523.473.53
Return on Assets-116.39-99.62-869.88-702.98-598.08-489.35
Return on Equity-161.86-131.52-2,099.56-1,236.83-1,163.67-767.20
Return on Invested Capital-48.52-58.58-26.91-33.59-28.97-297.30
Quick Ratio2.552.372.132.451.502.24
Current Ratio2.552.372.132.451.502.24

Cash flow, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q3
Net Income-4.88-6.93-3.11-4.84-5.32-52.21
Depreciation0.010.010.010.000.010.00
Other Funds (Non Cash)3.065.671.853.804.6351.90
Funds from Operations-1.81-1.25-1.25-1.03-0.68-0.31
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.10-0.050.25-0.910.650.18
Cash from Operating Activities-1.70-1.30-1.00-1.94-0.04-0.13
Capital Expenditures-0.00-0.00-0.00-0.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.00-0.00-0.00-0.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)---0.000.000.00
Change in Capital Stock2.131.210.963.310.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.131.210.963.310.000.00
Proceedsfrom Stock Options0.030.170.963.310.000.00
Issuance or Reduction of Debt, Net-0.020.03-0.06-0.790.020.21
Change in Long Term Debt-0.02-0.020.01-0.09-0.210.01
Issuance of Long Term Debt0.000.000.020.06-0.210.01
Reduction of Long Term Debt-0.02-0.03-0.00-0.150.000.00
Net Financing Active Other Cash Flow0.00-0.080.080.000.00-0.03
Other Financing Activities Uses0.00--0.000.00-
Cash from Financing Activities2.101.160.972.530.020.17
Exchange Rate Effect0.010.05-0.010.01-0.02-0.01
Net Change in Cash0.41-0.10-0.040.59-0.040.04
Free Cash Flow-1.70-1.30-1.01-1.94-0.04-0.13

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-30-0.0M-186.37K
2026-10-150.66%0.0M0.8M178.43K
2026-09-301.53%0.0M0.5M270.17K
2026-09-151.16%0.0M0.3M271.82K
2026-08-3113.44%0.0M0.3M540.26K
2026-08-141.73%0.0M0.3M387.84K
2026-07-310.64%0.0M0.3M384.56K
2026-07-154.25%0.0M0.3M390.56K
2026-06-300.83%0.0M0.2M296.17K
2026-06-1517.28%0.0M0.2M289.30K
2026-05-291.53%0.0M0.2M14.15K
2026-05-151.21%0.0M0.2M13.10K
2026-04-303.84%0.0M0.1M16.10K
2026-04-151.55%0.0M0.1M15.38K
2026-03-312.41%0.0M0.0M7.92K
2026-03-139.83%0.0M0.0M6.87K
2026-02-274.18%0.0M0.0M5.01K
2026-02-135.69%0.0M0.0M4.77K
2026-01-307.96%0.0M0.0M1.48K
2026-01-151.46%0.0M0.1M795

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-298-KCurrent report2026-10-23SEC
2026-10-21DEF 14CInformation Statement Pursuant to Section 14(c) of the Securities Exchange Act of 19342026-10-20SEC
2026-10-08PRE 14CInformation Statement Pursuant to Section 14(c) of the Securities Exchange Act of 19342026-10-08SEC
2026-10-05S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-09-2510-KAnnual report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-21DEF 14CInformation Statement Pursuant to Section 14(c) of the Securities Exchange Act of 19342026-08-20SEC
2026-08-05PRE 14CInformation Statement Pursuant to Section 14(c) of the Securities Exchange Act of 19342026-08-04SEC
2026-07-27EFFECTEffectiveness filing by commission orderSEC
2026-07-17S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-07-148-KCurrent report2026-07-08SEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-20EFFECTEffectiveness filing by commission orderSEC
2026-04-16CORRESPSEC
2026-04-15UPLOADUpload SubmissionSEC
2026-04-10S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-03-31DEF 14CInformation Statement Pursuant to Section 14(c) of the Securities Exchange Act of 19342026-03-31SEC
2026-03-20PRE 14CInformation Statement Pursuant to Section 14(c) of the Securities Exchange Act of 19342026-03-19SEC
2026-03-19PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-03-19SEC
2026-03-06424B3SEC
2026-02-268-KCurrent report2026-02-20SEC
2026-02-24EFFECTEffectiveness filing by commission orderSEC
2026-02-20CORRESPSEC
2026-02-19S-1/ASEC
2026-02-1710-QQuarterly report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-12CORRESPSEC
2026-02-10CORRESPSEC
2026-02-10UPLOADUpload SubmissionSEC
2026-02-02S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-01-30424B3SEC
2026-01-09EFFECTEffectiveness filing by commission orderSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
JANE STREET GROUP, LLC1.12%
CITADEL ADVISORS LLC0.53%
HRT FINANCIAL LP0.45%
StoneX Group Inc.0.18%
BANK OF MONTREAL /CAN/0.16%
Caitong International Asset Management Co., Ltd0.00%

Funds

Fund% owned
-

OakChart. PPCB. Cached 15 minutes.

Some panels did not load: ratings, insider.